This bill reauthorizes and expands the Accelerating Access to Critical Therapies for ALS Act through 2031, extending funding for research into treatments for amyotrophic lateral sclerosis. It requires drug manufacturers to share interim clinical trial data with the FDA to better assess the progress of investigational drugs and clarifies that phase 3 clinical trial definitions include combined phase 2/3 trials and planned trials not yet enrolling participants. The legislation also mandates the FDA to publish an updated five-year action plan for ALS and other rare neurodegenerative diseases, including resource needs and coordination strategies with broader disease communities. Additionally, the bill requires the Government Accountability Office to submit a report on the program's implementation four years after enactment.
Strengthening America’s Turning Point Act This bill renames the Saratoga National Historical Park, located in Stillwater, New York, as Saratoga National Battlefield Park.
The Main Street Capital Access Act reduces regulatory burdens for smaller banks, particularly those with less than $10 billion in assets. Key provisions include a 3-year phase-in period for new banks to meet capital requirements, lower leverage ratio requirements for rural banks (7.5% for the first 2 years), and a 30-day review process for business plan deviations. The bill also establishes an Office of Independent Examination Review, sets specific timelines for examinations (270 days) and reports (90 days), and creates a "least cost exception" for bank resolutions to prevent excessive concentration of the banking system. These changes aim to promote new bank formation, improve regulatory efficiency, and support community banking while maintaining financial stability.
This bill reauthorizes funding for the C.W. Bill Young Cell Transplantation Program, setting $31 million for fiscal year 2025 and $33 million annually for fiscal years 2027-2031. It also extends the deadline for the national cord blood inventory program from 2026 to 2031. The legislation directly affects stem cell research programs and cord blood banks by maintaining federal funding levels and prolonging the inventory program’s timeline. These provisions ensure continuity for existing research infrastructure and blood bank operations without introducing new policy changes.
This bill reauthorizes federal programs focused on preventing and responding to tick-borne diseases through 2026-2030, extending existing efforts beyond their previous expiration. It updates the National Strategy for Vector-Borne Diseases to emphasize identifying, reporting, preventing, and responding to these illnesses. The bill modifies two sections of the Public Health Service Act to continue funding for health departments working on vector-borne disease control. It directly affects public health programs and state/local health departments managing tick-borne disease prevention and response.
The AADAPT Act reauthorizes and expands Project ECHO grants to improve Alzheimer’s and dementia care through technology-enabled training. It specifically funds grants for healthcare providers in rural, frontier, or medically underserved areas to enhance early diagnosis, quality care, and provider retention for dementia patients. The bill authorizes $1 million annually (2027-2032) for these dementia-focused training programs, requiring funds to supplement - not replace - existing resources. This directly supports primary care providers licensed to serve underserved communities, using collaborative online learning to address care gaps.
This bill establishes the INCLUDE Project at the National Institutes of Health (NIH) to advance research on Down syndrome and related health conditions. It requires NIH to fund high-risk studies on trisomy 21, support inclusive clinical trials for people with Down syndrome across all ages, and investigate co-occurring conditions like Alzheimer’s disease and autoimmunity. The law mandates NIH coordination across its institutes, consultation with patient advocates, and biennial reports to Congress detailing funded research and its real-world applications. The project directly affects individuals with Down syndrome, their families, and medical researchers, aiming to improve diagnosis, treatment, and quality of life through targeted scientific efforts.
HR 3029, the Nucleic Acid Standards for Biosecurity Act, directs the National Institute of Standards and Technology (NIST) to develop new screening standards for synthetic DNA and RNA production to prevent misuse. It requires NIST to research improved testing accuracy, security protocols for sequence databases, and technical guidance for screening tools, with a stakeholder consortium including industry and researchers to set priorities. The bill authorizes $5 million annually (2026-2030) for NIST to carry out this work and mandates a report to Congress within 18 months of the first consortium meeting. This directly affects biotechnology companies, research institutions, and labs producing synthetic genetic materials by establishing new biosecurity screening requirements.
HR 2821, the FDA Modernization Act 3.0, requires the FDA to update regulatory language within one year of enactment. It directs the agency to replace all references to "animal tests" with "nonclinical tests" in 22 specific sections of the Code of Federal Regulations related to drug development and approval processes. The bill also adds a definition for "nonclinical test" into relevant FDA regulations to align with prior legislative changes. This update applies directly to pharmaceutical manufacturers and FDA reviewers who follow these regulatory guidelines during drug development. The changes aim to modernize terminology without altering current testing requirements.
This bill requires Medicare to create separate payment codes for ultralightweight manual wheelchairs based on their frame material (specifically titanium or carbon fiber vs. other materials), starting in 2026. It ensures Medicare pays the standard rate for titanium/carbon fiber wheelchairs regardless of material, while allowing suppliers to charge beneficiaries the difference between Medicare's payment and their actual cost. Beneficiaries must receive a notice about potential additional costs before purchasing or renting such wheelchairs. The bill directly affects Medicare beneficiaries needing these specialized wheelchairs and the suppliers who provide them.
HR 2913, the Ukraine Support Act, provides comprehensive U.S. support for Ukraine in response to Russia's invasion. The bill authorizes security assistance including lend-lease authority for military equipment, establishes a Ukraine Reconstruction Trust Fund for economic recovery, and imposes new sanctions targeting Russian financial institutions, oil companies, and government officials. It also includes provisions to counter Russian disinformation, support Radio Free Europe, and address the kidnapping of Ukrainian children. The legislation directly affects U.S. foreign policy, Ukraine's defense capabilities, and Russia's access to international financial systems. The act aims to strengthen Ukraine's sovereignty while holding Russia accountable for its actions.
This resolution honors the life and legacy of the late Senator Lindsey Olin Graham from South Carolina. It formally acknowledges his extensive career in the military, state government, and Congress, noting his service as a Senator and his roles as Chairman of the Judiciary and Budget committees. The Senate expresses its sorrow over his death and requests that this tribute be shared with the House of Representatives and Graham's family.
